Pharmacological treatment of metabolic dysfunction–associated steatotic liver disease: a narrative review
Journal of the Korean Medical Association · 10.06.2026 · 69 (6) · 492-501
DOI: 10.5124/jkma.26.0043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Korean Medical Association, erschienen am 10.06.2026. Verfasst von Jeong-Hwan Lee und 3 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Soonchunhyang University.
Abstract (Originalsprache)
Purpose: Metabolic dysfunction–associated steatotic liver disease (MASLD) is one of the most prevalent chronic liver diseases worldwide, with a rising incidence driven by obesity and type 2 diabetes. Because progression to advanced fibrosis is the primary determinant of long-term outcomes, there is an increasing need for effective pharmacological therapies. This review summarizes current pharmacological treatment strategies for MASLD and emerging therapeutic approaches.Current concepts: Management of MASLD is based on risk stratification according to fibrosis stage and metabolic risk factors. Although lifestyle modification remains the cornerstone of treatment, pharmacological therapy is considered in patients with metabolic dysfunction–associated steatohepatitis (MASH) and/or significant fibrosis. Conventional agents, such as pioglitazone and vitamin E, improve hepatic steatosis and inflammation; however, their antifibrotic effects remain limited. More recently, disease-modifying therapies such as resmetirom have demonstrated improvements in both MASH resolution and fibrosis. Incretin-based therapies, including glucagon-like peptide-1 receptor agonists, have also shown favorable metabolic and histological effects and have gained regulatory attention based on surrogate endpoints.Discussion and conclusion: Despite recent advances, most available therapies have limited antifibrotic efficacy, underscoring the need for more effective treatment strategies. Emerging agents targeting diverse pathways—including fibroblast growth factor 21 analogs, dual incretin agonists, and pan–peroxisome proliferator–activated receptor agonists—are under active investigation. Future management of MASLD is expected to evolve toward a personalized approach based on fibrosis stage and metabolic risk, with increasing emphasis on combination therapies and antifibrotic strategies to modify disease progression.
Förderung
- Soonchunhyang University
Zitieren
APA
Lee, J., Yoo, J., Kim, S. G., & Kim, Y. S. (2026). Pharmacological treatment of metabolic dysfunction–associated steatotic liver disease: a narrative review. Journal of the Korean Medical Association, 69(6), 492-501. https://doi.org/10.5124/jkma.26.0043
Vancouver
Lee J, Yoo J, Kim SG, Kim YS. Pharmacological treatment of metabolic dysfunction–associated steatotic liver disease: a narrative review. Journal of the Korean Medical Association. 2026;69(6):492-501. doi:10.5124/jkma.26.0043
BibTeX
@article{Lee2026,
author = {Lee, Jeong-Hwan and Yoo, Jeong-Ju and Kim, Sang Gyune and Kim, Young Seok},
title = {Pharmacological treatment of metabolic dysfunction–associated steatotic liver disease: a narrative review},
journal = {Journal of the Korean Medical Association},
year = {2026},
volume = {69},
number = {6},
pages = {492--501},
doi = {10.5124/jkma.26.0043}
}
EUVIMED